Skip to main content
Clinical Trials/NCT07292662
NCT07292662
Recruiting
Not Applicable

TAP Block Versus ESP Block in Patients Undergoing Elective Cesarean Section: a Randomized Controlled Trial

University of Padova1 site in 1 country90 target enrollmentStarted: January 7, 2026Last updated:
InterventionsESP blockTAP block

Overview

Phase
Not Applicable
Status
Recruiting
Sponsor
University of Padova
Enrollment
90
Locations
1
Primary Endpoint
Pain at Rest at 6 hours

Overview

Brief Summary

This study is comparing two types of pain relief techniques-TAP block and ESP block-for women having an elective cesarean section. Both techniques involve injecting local anesthetic under ultrasound guidance to numb nerves and reduce pain after surgery. The TAP block mainly relieves pain in the abdominal wall, while the ESP block may reduce both abdominal wall and deeper, organ-related pain. The main goal is to see if there's a difference in pain at rest six hours after surgery. The study will also look at pain at later time points, the amount of opioid medication needed, how quickly women can walk, and when they start breastfeeding.

A total of 156 women will be randomly assigned to receive one of the two blocks after standard spinal anesthesia. Pain will be measured using a simple 0-10 scale at 6, 12, and 24 hours, both at rest and during movement. The study follows strict ethical rules, ensures patient privacy, and all results-whether positive or negative-will be shared to help improve pain management after cesarean delivery.

Detailed Description

This study is a prospective, monocentric, randomized controlled trial designed to compare the analgesic efficacy of the transversus abdominis plane (TAP) block versus the erector spinae plane (ESP) block in women undergoing elective cesarean section. Cesarean delivery, one of the most commonly performed surgical procedures worldwide, is associated with both somatic and visceral postoperative pain. Optimizing pain control is critical not only for maternal comfort but also for reducing complications, facilitating early mobilization, and supporting breastfeeding and maternal-infant bonding. While the TAP block provides effective somatic analgesia of the abdominal wall with a rapid learning curve, it does not address visceral pain. Conversely, the ESP block offers multidermatomal coverage, potentially reducing both somatic and visceral components of postoperative pain and opioid consumption. The primary objective of the study is to evaluate postoperative pain at rest six hours after surgery, with secondary outcomes including pain at various time points, opioid consumption, time to first rescue analgesia, ambulation, and initiation of breastfeeding.

A total of 156 patients meeting inclusion criteria (age 18-45 years, elective cesarean, informed consent) will be randomized to receive either a bilateral TAP or ESP block following standardized spinal anesthesia. Pain scores will be assessed using an 11-point Numeric Rating Scale (NRS) at 6, 12, and 24 hours postoperatively, both at rest and with movement. Opioid use, time to ambulation, and breastfeeding initiation will also be recorded. The study is powered to detect a clinically significant difference in pain scores, and data analysis will include tests for normality, parametric and non-parametric comparisons, repeated-measures analysis, regression models, and survival analysis for time-to-event outcomes. The trial adheres to ethical standards, including informed consent and data privacy, and the results will be disseminated regardless of outcome, contributing to evidence-based practice in post-cesarean analgesia.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Investigator, Outcomes Assessor)

Masking Description

Outcome assessor and investigator will be blind of the procedure as each patient will be associated with an unique ID.

Patients and patient care provider could not be blind given the nature of the procedure

Eligibility Criteria

Ages
18 Years to 45 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age between 18 and 45 years
  • Elective cesarean section
  • Ability to provide informed consent

Exclusion Criteria

  • Allergy to any of the drugs used in the study
  • Heart disease with impaired cardiac function
  • Stage III or higher kidney failure
  • Coagulation disorders (platelets \<100,000/μL or INR \>1.5) or severe liver disease
  • Degenerative central nervous system diseases or peripheral neuropathies
  • Previous uterine surgery (e.g., myomectomy)
  • Previous cesarean section
  • Pre-pregnancy weight \<55 kg

Arms & Interventions

ESP block

Experimental

Patients will undergo preoperative bilateral ESP block with ropivacaine 0.375% 20 mL per side (total 40 mL)

Intervention: ESP block (Procedure)

TAP block

Active Comparator

Patients will undergo preoperative bilateral TAP block with ropivacaine 0.375% 20 mL per side (total 40 mL)

Intervention: TAP block (Procedure)

Outcomes

Primary Outcomes

Pain at Rest at 6 hours

Time Frame: 6 hours after end of surgery

Pain measured at Rest with Numeric Rating Scale (minimun 0- maximum 10) with 0 meaning no pain and 10 high pain

Secondary Outcomes

  • Pain at Rest at 12 hours(12 hours after end of surgery)
  • Pain at Rest at 24 hours(24 hours after end of surgery)
  • Pain at Movement at 6 hours(6 hours after end of surgery)
  • Pain at Movement at 12 hours(12 hours after end of surgery)
  • Pain at Movement at 24 hours(24 hours after end of surgery)
  • Milligram of Morphine equivalents in the first 24 postoperative hours(from the end of the surgery to 24 hours after the surgery)
  • Time to rescue analgesic requirement(Form the end of the surgery to the first rescue analgesic requirement (up to o 24 hours after the surgery))
  • Time to breast feeding(Form the end of the surgery to the start of breast feeding (up to o 24 hours after the surgery))
  • Time to deambulate(Form the end of the surgery to the start of deambulation (up to o 24 hours after the surgery))

Investigators

Sponsor
University of Padova
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Alessandro De Cassai

Principal Investigator

University of Padova

Study Sites (1)

Loading locations...

Similar Trials